Nivolumab Improves Survival Over Chemotherapy in Esophageal Squamous Cell Carcinoma

At the ESMO 2019 Congress, Byong Chul Cho, MD, PhD, Yonsei Cancer Center, Seoul, South Korea, discusses results from the phase 3 ATTRACTION-3 study, which showed improved OS and safety with nivolumab over chemotherapy for patients with previously treated esophageal squamous cell carcinoma.

https://www.oncnet.com/videos/nivolumab-improves-survival-over-chemotherapy-esophageal-squamous-cell-carcinoma

Leave a comment



Leave a Reply

Your email address will not be published. Required fields are marked *